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Summan- Because genetic predisposition probably plays an important role in the aetiology of most of
childhood cancers. studies of second primaries occurring after these cancers may be particularly informative
about possible common genetic mechanisms in both of these cancers. We have studied the incidence of thyroid
tumours occumng after cancer in childhood in a cohort of 592 children treated before 1970. Among these
children. six later developed a thyroid carcinoma, and 18 developed a thyroid adenoma. Radiation doses
received to the thyToid by each of the irradiated children have been estimated using individual radiotherapeutic
technical records. Thyroid carcinomas and thyroid adenomas were five times more frequent after irradiation
for neuroblastoma than after irradiation for anv other first cancer. This ratio did not depend on sex. nor on
time elapsed since irradiation. nor on dose of radiation received for the thyToid gland. This result suggests that
there is a common mechanism for the occurrence of neuroblastoma and of differentiated thyroid tumour.
Epidemiological studies of second primary cancers may be of
great help in improving the knowledge of carcinogenesis.
because evidence for association between two types of cancer
may lead to the formulation of hypotheses concerning com-
mon mechanisms in both of these cancers. The observation
of an excess incidence of osteosarcoma after bilateral retino-
blastoma has led to the suggestion that the anti-oncogene
Rb. which controls for retinoblastoma. played a role in the
development of osteosarcoma. and this role has been demon-
strated later (Knudson. 1971: Hansen et al.. 1985).
If such an association between two cancers is less strong. a
cohort study including several types of first cancers needs to
be organised in order to identify this association and to be
able to adjust for the carcinogenic effects of the first cancer
treatment.
We report here the results of a cohort study monitored in
order to analyse the risk of thyroid tumour after a first
cancer in childhood.
Methods
Patients
This study included all the 592 children treated for a cancer
at the Gustave-Roussy Institute (IGR) between 1942 and
1969 and who were alive and free of disease 5 years after
diagnosis, excluding 22 children treated for a thyroid cancer
and 20 who had received brachytherapy. Those latter 20
children were excluded in order to include only patients
treated with the same type of radiation at a similar dose rate.
The diagnosis of cancer was confirmed by histology, cytology
and measurements of tumour marker levels, or clinically
when a tumour sample was not available, notably for brain
tumours. The absence of children treated for leukaemia
(Table I) is due to the fact that IGR is an important
reference centre in France for solid paediatric cancers. All
children were followed-up by one of us (O.S.). Only clinically
apparent tumours of the thyroid gland were recorded.
Dosimetry
The dose and duration of each drug received by the 592
children. and information on radiotherapy were extracted
from medical records (Table I). Of the 592 children. 496
received X or gamma radiation. For each of these patients.
the radiation doses to the two lobes of the thyroid gland
were estimated retrospectively using individual radiothera-
peutic technical records. The estimation involved two steps.
The first step estimated the position of the two lobes of the
thyroid gland from the size of the child at time of treatment,
using a child phantom model based on auxometrical curves
(Francois et al.. 1989a). The second step used a model which
describes the variation of the dose in and outside the treat-
ment beam. taking into account the quality of the radiation.
the characteristics of the treatment machine (collimator and
machine head construction) and the field shape (Francois et
al.. 1989b). For each of the children in the studv. data for
this second step were obtained from the technical reports and
from the controls films.
Statistical methods
The cumulative incidence of thyroid tumour was estimated
using the Kaplan-Meier method (Kaplan & Meier. 1958).
The analysis of risk for given categories was performed
using the Cox's regression model (Cox. 1972). The relation-
ship between the dose of radiation received to the thyroid
and the risk of thyroid tumour was studied using Poisson
regression model of the excess of relative risk of thyroid
tumour as a linear function of the dose. and a multiplicative
function of other factors. This model was fitted using Epicure
software (Preston et al.. 1990).
Results
At the end point of the study. 1 January 1986. 152 patients
(26%) were lost to follow-up 80 (14%) before January 1982.
The median follow-up from diagnosis of first cancer was 22
years (range: 5 to 40).
None of the 96 non-irradiated patients developed a thyroid
tumour. Of the 496 irradiated patients. 24 developed an
epithelial thyroid tumour. This leads to a cumulative inci-
dence of thyroid tumour, 25 years after irradiation, equal to
8.1%. with a 95% confidence interval (CI) of 4.7- 13.8%. Of
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Table I Age. sex. and modalities for treatment of592 children treated at Gustave Roussy Institute for a first cancer, and alive and free ofdisease 5
years after diagnosis
Radiotherapy
Median
age at Median Chemotherapy
first Type ofenergy dose at Median Median Alkvlating
.Males cancer LEXR COB HEXR e- thiroid number of duration An! tipe agents
First cancer (n) (0 v range n (n v n) (n) (n) (cGY) fractions (daYs) (n) (n)
All types (592) 53 3 (0-17) 496 246 166 100 36 50 18 36 303 122
Neuroblastoma (99) 54 0 (0-16) 75 43 14 10 13 52 12 21 65 62
Other (493) 52 4 (0-17) 421 203 152 90 23 50 19 38 238 60
Wilm's tumour (175) 51 2 (0-14) 165 103 27 51 2 39 15 38 126 1
Hodgkin's disease (38) 63 10 (2-14) 36 2 36 2 3 1533 18 37 28 19
Brain tumour (80) 45 7 (0-17) 80 44 17 28 1 93 21 43 12 1
Non-Hodgkin's lymphoma (32) 59 7 (0-14) 27 9 18 1 4 173 18 35 14 13
Bone sarcoma (39) 67 9 (0-14) 29 4 26 0 1 17 24 42 10 8
Soft tissue sarcoma (62) 45 3 (0-14) 40 19 12 1 4 22 18 32 23 4
Other cancer (67) 52 2 (0-14) 44 22 16 6 5 47 19 37 25 14
'Some patients have received more than one type of energy. LEXR = low energy X-rays; COB = cobalt 60; HEXR = High energy X-rays:
e- = electrons.
these 24 thyroid tumours. six were differentiated thyroid
carcinomas and 18 were adenomas: this ratio of benign to
malignant is similar to what has been reported in irradiated
patients (Shore et al.. 1985) by other authors. We shall
consider thyroid adenomas and carcinomas together in the
rest of the study because of the small number of thyroid
tumours observed and because the dose-response relationship
between radiation and the risk of thyroid tumours has been
found to be similar for adenomas and carcinomas by Shore
et al. (1985) and of the same magnitude by Tucker et al.
(1990).
Thyroid tumours were much more frequent after irradia-
tion for neuroblastoma. 11 of 75 patients. than after irradia-
tion for other cancer. 13 of 421 patients. This higher
incidence of thyroid tumours after neuroblastoma was ob-
served during the 30 years of follow-up (Figure 1). and
existed both for carcinomas (3 75 vs 3 421) and for adenomas
(8 75 vs 10421).
When taking into account the other factors, no effect of
age at irradiation was found (RR for children aged less than
2 years compared with others: 0.93):8 53 (15%) of the
neuroblastoma patients treated under age of 2 years devel-
oped a thyroid tumour compared with 3 22 (12%) in the
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Fiwe 1 Cumulative incidence rate of thyroid tumour and 95%
confidence interval (95% CI), by type of first cancer, in a popula-
tion of 496 patients irradiated for a first cancer in childhood.
older patients. these proportions being respectively 300 and
30% for non-neuroblastoma.
No effect ofchemotherapy. of any type of alkylating agent
or of any other drug was found.
Controlling for possible differences in sex. time elapsed
since irradiation (20 or >years) and radiation dose to the
thyroid (in cGy). the risk ofdeveloping a thyroid tumour was
found to be 5.0 times higher (95% CI: 3.3-7.5) for children
irradiated for a neuroblastoma than for other children. Table
II presents the risk of thyroid tumour as a function of the
dose. for neuroblastoma and for other tumours.
When fitting the excess of relative risk of thyroid tumour
as a linear function of the dose of radiation received to the
thyroid and as a multiplicative function of sex. tyipe of first
cancer (neuroblastoma or not). and follow-up, no interaction
was found between effect of sex or neuroblastoma and that
of dose: the same linear coefficient for the dose was found
whatever the sex and the type of first cancer. This result
implies that women and children treated for neuroblastoma
would have a more important spontaneous rate of thyroid
tumour rather than a more important radiosensibility of the
thyroid. Figure 2 presents the relative risks in Table II. and
those predicted from a linear relationship using the same
coefficient for neuroblastoma and other tumours.
As previously reported (de Vathaire et al.. 1988. 1989a.b).
excluding thyroid tumours, no more second tumours were
found after irradiation for a neuroblastoma (three of 75)
than for other type of first cancer (24 of 421) (RR = 0.80).
Contrary to other authors (Cohen et al.. 1990). we did not
find any parathyroid adenoma associated with the thyroid
tumours.
Dscussio
Our results were not affected by the important proportion of
subjects lost to follow-up (22%): under the extreme assump-
tion, more probable in France, that all children lost to
follow-up were alive and free of thyroid tumour at the end of
1985. the relative risk of thyroid tumour was 4.2 (95% CI:
1.9-9.5) for neuroblastomas, compared with that for other
tumours.
Tucker et al. (1991) suggested an excess of thyroid cancers
after dactinomycin. We not confirm this result.
The two other studies of second thyroid tumours after
cancer treatment considered only thyroid carcinomas and not
adenomas. The Late Effect Study Group (Tucker et al.. 1984:
1991), a hospital-based study. observed seven second thyroid
cancers among the 790 patients irradiated for neuroblastoma.
compared with 16 among the 8.380 others. When the dose
received to the thyroid was not taken into account, the risk
of thyroid cancer was found to be 7.7 times higher afterNEUROBLASTOMA AND DIFFERENTIATED THYROID TUMOUR 427
Table I Risk of thyroid tumour according to the type of first cancer and to the dose of radiotherapy received at the thyroid gland
Radiotherapy dose to the thyroidgland in cGY (median dose)
0 0.1-50 51-100 101-500 501-2000 2001-4192
First cancer tipe (no radiotherapyv (24) (67) (157) (1299} (2419)
Neuroblastomas
Thyroid tumours number of patients 0 24 2 37 1 12 2 15 4 8 2 3
Mean annual incidence of thyroid tumour per 10
personSb 0 46 54 86 336 444
Risk of thyroid tumour relative to the reference
category (95% CI) - 6.6 (1.1-40) 5.2 (0.5-50) 9.5 (2-59) 26 (6-119) 58 (9-357)
Non-neuroblastomas
Thyroid tumours number of patients 0 71 3 124 1 61 2 58 5 71 2 17
Mean annual incidence of thyToid tumour per 104
personsb 0 7.2 7.8 21 54 106
Risk of thyroid tumour relative to the reference
category (950o CI)' - a 0.9 (0.2-12) 1.5 (0.3-9) 7.2 (1.7-30) 20 (3.3-125)
aReferencecategory: bThe first 5 years following irradiation were excluded.'The relative risk ofthyroid tumour is the ratio between therisk for the
dose range considered and the risk in the reference category, namely non-neuroblastoma having received between 0.1 and 50 cGY. All relative risks
were adjusted on sex and were estimated through Cox's regression model.
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Figre 2 Relative n'sk of thyroid tumour as a function of the
radiation dose. bv type of first cancer. logarithmic scale. The
symbols represent. in a log-log scale. the relative risk of thyroid
tumour (given in Table II) as a function of the dose to thyroid
(0) = the risk for children treated for a neuroblastoma. * = the
nsk for children treated for another type of cancer. The curves
correspond to Poisson regression models of the excess of relative
risk of thyroid tumour as a linear function of the dose. For
non-neuroblastomas. the model is: relative risk = 0.0055*dose.
For children treated for a neuroblastoma. the model is: relative
risk = 5.0 + 0.0055* dose. Where the dose is expressed in cGv
and the n'sk is expressed relatively to a risk for a zero dose to the
thyroid. The addition of a quadratic function of the dose or of an
interaction term between the dose and the type of first cancer
(non-parallelism of the two dose-response relationships). did not
significantly improve the fit of the model (respectivelv. =0.1;
P=0.8. and j=0.l1 P=0.8).
treatment for neuroblastoma than for other types of first
cancer. When the dose received to the thyroid was taken into
account, the authors found a rate of 2.1 thyroid cancers per
person-years cGY after neuroblastoma. 1.6 after Wilms'
tumour, 0.3 after Hodgkin's disease, and 0.3 after non-
Hodgkin's lymphoma. Nevertheless, they were not able to
control directly for differences in the dose to the thyroid
between the different types of first cancers; the estimation of
the dose of radiation to the thyroid was conducted on cases
of thyroid cancer and on controls matched for type of first
cancer. Hence, the estimations of rates per person-years cGy
for the cohort seem to have been made by extrapolating the
mean doses obtained for the controls and the cases in the
case-control study to the entire cohort, and are imprecise. In
a British registry-based cohort study (Hawkins et al., 1987)
involving more than 10,000 3-year survivors of childhood
cancer, only three thyroid cancers were observed. No thyroid
cancers were observed after a median follow-up of 13. 5 years
among the 134 irradiated neuroblastomas. As a rule, more
second cancers, and particularly more thyroid cancers. are
found in hospital based-studies than in registry-based studies
because of differences in treatment intensity and in extent of
diagnostic investigations during follow-up. This difference in
frequency is strongly increased for thyroid adenomas. whose
diagnosis is difficult, and depends on the importance of
nuclear medicine units, that have been particularly developed
at IGR.
There are biological arguments supporting a relationship
between thyroid tumours and neuroblastomas. Firstly, the
tumours of the sympathetic system (pheochromocytomas
and, in rare instances, neuroblastomas) can be associated
with medullary thyroid carcinoma (Sipple, 1961). Secondly.
there is evidence that C cells and epithelial thyroid cells share
a common embryological origin (Caillou et al.. 1981). Third-
ly, similar chromosomal deletions or abnormalities have been
found in medullary thyroid carcinomas and in epithelial
thyroid tumours (Jenkins et al., 1990).
The higher incidence of thyroid cancer after neuroblastoma
suggests a common mechanism for the occurrence of neuro-
blastoma and of differentiated thyroid tumour. This would
imply an increased risk of thyroid tumour among non-irrad-
iated neuroblastoma patients. Our series includes only 24
such children; even with a relative risk of 7.5 (upper level of
the 95% CI of our estimation of 5.0) and with a ratio of 10
adenomas for one carcinoma (Van Herle et al., 1982). The
expected number of thyroid tumours among these 24 children.
based on incidence rates from the national registry of Den-
mark (there is no national cancer incidence registry in
France). is 0.39 and the probability of observing no thyroid
tumour is 67%.
We observe an excess risk of thyroid cancer after neuro-
blastoma which could be compared with the excess of osteo-
sarcoma after bilateral retinoblastoma. Nevertheless, the
mechanism of the association between thyroid tumour and
neuroblastoma is probably different for two reasons. First,
neuroblastoma does not present in a familial form. Second,
bilateral or generalised neuroblastomas do not provide a
higher risk of thyroid tumour: among the 75 irradiated
neuroblastoma patients in our series, three were bilateral and
12 were generalised, of which none developed a thyroid
tumour.
Tucker et al. (1987) found the relationships between the
dose of radiation received by a given bone and the risk of
osteosarcoma in this bone, to be of similar shape after
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bilateral retinoblastoma and after unilateral retinoblastoma
or other first cancer. We observed likewise the relationship
between the dose to the thyroid and the risk of thyroid
tumour to have similar shapes after neuroblastomas and after
other cancers (Figure 2). This is an argument against the
hypothesis that the effects of radiation on the two alleles of
an anti-oncogene controlling for a radio-induced cancer
(bone cancer after retinoblastoma or thyroid tumour after
neuroblastoma) are independent. Such independence. and the
linear dose-response relationship observed for patients with
germinal mutation. would imply a quadratic relationship for
the other patients. contrary to what is observed.
Attention should be paid to the fact that both our results.
and those found for osteosarcomas are bilateral retinoblas-
tomas, only concern situations in which the total dose is
delivered by fractions of several minutes each. Repair mech-
anisms take place between each fraction and results, partic-
ularly for the dose-effect relationship. could possibly be
different if the total dose was given in one fraction. Further-
more. our results have to be confirmed by a study including
more children.
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